Should You Buy AbbVie Stock Before April 29?

Key Points
AbbVie's growth rate has been impressive given the headwinds it has faced.
This year, it's forecasting a significant increase in its earnings.
- 10 stocks we like better than AbbVie ›
AbbVie (NYSE: ABBV) is a leading drugmaker that investors have come to rely on for steady and consistent results over the years. Along the way, it has also paid and increased its dividend on a regular basis. It's been one of the better healthcare stocks to own, and it has nearly doubled in value in just five years.
This year, it's been off to a tough start, declining by around 10%. But the company reports earnings later this month, and a strong performance could give investors a reason to load up on the stock. Should you buy shares of AbbVie before it releases its latest earnings numbers on April 29?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The company's growth rate has been trending upward
AbbVie has faced some significant challenges in recent years, most notably with the loss of patent protection on its top-selling drug, Humira. The company, however, has shown that it can continue growing amid the lost revenue. New drugs Skyrizi and Rinvoq are doing exceptionally well, and AbbVie has bolstered its business via acquisitions in recent years. The end result is a more diversified healthcare company, and its growth rate has been picking up the pace in recent quarters.
Meanwhile, on the bottom line, things look even better. This year, the company is projecting its adjusted diluted earnings per share (EPS) will be within a range of $13.96 to $14.16, which would be a significant increase from 2025, when its adjusted diluted EPS was $10.00.
Why AbbVie stock makes for an underrated buy right now
AbbVie's stock hasn't been getting much love from investors for its strong results amid adversity. Its top line may look unimpressive in recent years, but that's with the company facing some considerable challenges related to Humira. A strong performance in the first quarter of 2026 could be just what the healthcare stock needs to remind investors of the solid investment that it is.
While its valuation looks high, with AbbVie trading at a price-to-earnings multiple of 88, that's largely due to the effects of one-time expenses as a result of acquisitions. Based on analyst expectations of future earnings, however, it's trading at an earnings multiple of just 14.
AbbVie's stock is a solid long-term buy for its growth opportunities and high-yielding dividend, which currently pays 3.3% (the S&P 500 average is only 1.2%). And the company has tripled the rate of its quarterly payout over the past decade. Whether you want reliable dividend income or to take advantage of its long-term growth potential, AbbVie is a solid investment you can hang on to for years.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,087,496!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 7, 2026.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.